Thursday - October 30, 2025
Datroway Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival as 1st-Line Therapy for Patients With Metastatic Triple-Negative Breast Cancer for Whom Immunotherapy Was Not an Option in TROPION-Breast02
October 07, 2025
WILMINGTON, Delaware, Oct. 7 -- AstraZeneca, a biopharmaceutical company, issued the following news release:

* * *

DATROWAY (datopotamab deruxtecan-dlnk) demonstrated statistically significant and clinically meaningful improvement in overall survival as 1st-line therapy for patients with metastatic triple-negative breast cancer for whom immunotherapy was not an option in TROPION-Breast02

AstraZeneca and Daiichi Sankyo's DATROWAY is the first and only t . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products